Abstract
BackgroundPlatinum-resistant ovarian cancer patients have a poor prognosis and few treatment options are available. Preclinical and clinical data demonstrated that the combination of poly-ADP ribose polymerase inhibitors with immune checkpoint...
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have